Very high response rates in previously untreated T-cell prolymphocytic leukaemia patients receiving Alemtuzumab (Campath-1H) therapy.

被引：0
|
作者：
Dearden, CE
Matutes, E
Cazin, B
Ireland, R
Parreira, A
Lakhani, A
Catovsky, D
机构：
[1] Royal Marsden Hosp, London SW3 6JJ, England
[2] Hosp C Huriez, Lille, France
[3] Queen Elizabeth Hosp, Woolwich, England
[4] Inst Oncol, Lisbon, Portugal
[5] Farnborough Hosp, Farnborough, Hants, England
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2378
引用
收藏
页码：644A / 644A
页数：1
相关论文
共 32 条
  • [1] Longer follow up of T-prolymphocytic leukaemia patients treated with Alemtuzumab (CAMPATH-1H) shows improved survival and higher response rates in previously untreated patients.
    Dearden, CE
    Matutes, E
    Cazin, B
    Tjonnfiord, GE
    Parreira, A
    Leoni, P
    Rassam, SMB
    Roques, T
    Ketterer, N
    Lakhani, A
    Catovsky, D
    BLOOD, 2002, 100 (11) : 364A - 364A
  • [2] High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H
    Dearden, CE
    Matutes, E
    Cazin, B
    Tjonnfjord, GE
    Parreira, A
    Nomdedeu, B
    Leoni, P
    Clark, FJ
    Radia, D
    Rassam, SMB
    Roques, T
    Ketterer, N
    Brito-Babapulle, V
    Dyer, MJS
    Catovsky, D
    BLOOD, 2001, 98 (06) : 1721 - 1726
  • [3] CAMPATH-1H therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).
    Lundin, J
    Björkholm, M
    Celsing, F
    Hale, G
    Hjalmar, V
    Kimby, E
    Tullgren, O
    Waldman, H
    Mellstedt, H
    Österborg, A
    ANNALS OF ONCOLOGY, 2000, 11 : 96 - 96
  • [4] CAMPATH-1H therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).
    Mellstedt, H
    Österborg, A
    Lundin, J
    Björkholm, M
    Celsing, F
    Hagberg, H
    Hast, R
    Hjalmar, V
    Kimby, E
    Luthman, M
    Tullgren, O
    Werner, B
    BLOOD, 1998, 92 (10) : 490A - 490A
  • [5] Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).
    Lundin, J
    Kimby, E
    Bjorkholm, M
    Celsing, F
    Hale, G
    Hjalmar, V
    Merup, M
    Petrescu, A
    Tullgren, O
    Waldmann, H
    Mellstedt, H
    Osterborg, A
    BLOOD, 2001, 98 (11) : 772A - 772A
  • [6] Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed
    Keating, MJ
    Cazin, B
    Coutré, S
    Birhiray, R
    Kovacsovics, T
    Langer, W
    Leber, B
    Maughan, T
    Rai, K
    Tjonnfjord, G
    Bekradda, M
    Itzhaki, M
    Hérait, P
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) : 205 - 213
  • [7] Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: Correlation between low T-cell responses and infection
    Thai, Ngoc L.
    Blisard, Deanna
    Tom, Kusum
    Basu, Amit
    Smetanka, Cindy
    Tan, Henkie
    Bentlejewski, Carol
    Glidewell, Janice
    Britz, Judy
    Kowalski, Richard
    Shapiro, Ron
    Fung, John
    Marcos, Amadeo
    Zeevi, Adriana
    TRANSPLANTATION, 2006, 82 (12) : 1649 - 1652
  • [8] Alemtuzumab (campath-1H) in patients with erythrodermic cutaneous T-cell lymphoma (E-CTCL): The Northwestern University experience.
    Querfeld, Christiane
    Rosen, Steven T.
    Guitart, Joan
    Martone, Brenda
    Rademaker, Alfred
    Kuzel, Timothy M.
    BLOOD, 2006, 108 (11) : 772A - 773A
  • [9] Alemtuzumab (Campath 1-H) in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma
    Sharma, Kamal
    Janik, John E.
    O'Mahony, Deirdre
    Stewart, Donn
    Pittaluga, Stefania
    Stetler-Stevenson, Maryalice
    Jaffe, Elaine S.
    Raffeld, Mark
    Fleisher, Thomas A.
    Lee, Cathryn C.
    Urquhart, Nicole
    Steinberg, Seth
    Waldmann, Thomas A.
    Morris, John C.
    BLOOD, 2008, 112 (11) : 701 - 701
  • [10] Combination of 9-aminoacridine with Campath-1H provides effective therapy for a murine model of adult T-cell leukemia
    Ju, Wei
    Zhang, Meili
    Petrus, Michael
    Maeda, Michiyuki
    Pise-Masison, Cynthia A.
    Waldmann, Thomas A.
    RETROVIROLOGY, 2014, 11
1234